Glenmark Sets Sights On Regional Out-Licensing, Lot Riding On US Rhinitis NDA
Executive Summary
With a basket of interesting R&D assets in hand, India’s Glenmark says it is pursuing regional out-licensing deals, including in Japan and China, for some of its molecules. Expectations are also running high on the firm’s first US NDA submission for seasonal allergic rhinitis.
You may also be interested in...
Asia Deal Watch: Takeda Licenses Curadev STING Agonist To Further Its IO Ambitions
The Japanese pharma, continuing to bolster its pipeline after buying Shire, is partnering with Skyhawk in neurodegenerative diseases under another new deal. Also, Purdue cites shifting business priorities for a decision to end Eisai collaboration on sleep disorder drug.
Glenmark, Yuhan Partner for Ryaltris, Eyes On US Trajectory
Glenmark has kicked off 2019 with more regional deal-making, sealing an alliance for its investigational rhinitis asset with Yuhan in South Korea. But the outlook for the fixed-dose combination nasal spray also hinges on its US approval.
Glenmark Spins Out Business To Drive Value
Glenmark has drawn private equity interest for its carved out domestic orthopedic and pain management business as it seeks to fuel growth in these segments and pare debt via the proceeds. A similar strategy may be deployed for the firm's active pharmaceutical ingredients unit.